A Clinical Development Paradigm for Cancer Vaccines and Related Biologics
Axel Hoos(GlaxoSmithKline (United States)), Geoffrey Nichol(Genesys (United States)), A Eggermont(Erasmus MC), Kristen Hege(University of California, San Francisco), Giorgio Parmiani(Fondazione IRCCS Istituto Nazionale dei Tumori), Mario Sznol(Yale University), Brent A. Blumenstein(Dana-Farber Cancer Institute), Natalie Sacks(Genesys (United States)), Hans Loibner, Ulrich Keilholz(German Cancer Research Center), Walter J. Urba(Providence Portland Medical Center)
Cited by 271
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k